Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study.

A nested case-control study of invasive and in situ cervical cancer was performed within a community-based cohort of 13,595 Taiwanese women assembled in 1991, with a follow-up period of 9 years. Baseline serum or plasma samples were analysed for antibodies against human papillomavirus (HPV) types 6, 16 and 18 and Chlamydia trachomatis. In total, 114 cases (42 incident cases identified during follow-up and 72 prevalent cases identified at baseline) and 519 matched controls were included in the study. HPV-16 seropositivity was strongly associated with cervical cancer (OR=6.33; 95% CI 3.45-11.62). Overall, C. trachomatis was not associated with cervical cancer, but was associated with cervical cancer in analyses restricted to incident cases of cancer (OR=2.94; 95% CI 1.17-7.42) or to cases in which serum samples were analysed (OR=3.13; 95% CI 1.16-8.47). An antagonistic interaction between HPV-6 and -16 was found in a multiplicative model. These results suggest that different HPV types might interfere in cervical carcinogenesis and that C. trachomatis is associated with cervical cancer in prospective studies, and support the notion that HPV-16 seropositivity is strongly associated with cervical cancer.

[1]  F. Wiklund,et al.  Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer , 2006, International journal of cancer.

[2]  J. Dillner,et al.  Chlamydia trachomatis infection and persistence of human papillomavirus , 2005, International journal of cancer.

[3]  R. Peeling,et al.  Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case‐control study , 2004, International journal of cancer.

[4]  J. Dillner,et al.  Human papillomavirus genotypes in cervical cancers in Mozambique. , 2004, The Journal of general virology.

[5]  T. Bjørge,et al.  Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. , 2004, European journal of cancer.

[6]  J. Dillner,et al.  A population-based study of cervical carcinoma and HPV infection in Latvia. , 2004, Gynecologic oncology.

[7]  S. Franceschi,et al.  Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis , 2003, British Journal of Cancer.

[8]  Y. Taketani,et al.  IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: Case‐control study of cervical intraepithelial neoplasia in Japan , 2003, Journal of medical virology.

[9]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[10]  Joakim Dillner,et al.  Evaluation of cost-precision rations of different strategies for ELISA measurement of serum antibody levels. , 2002, Journal of immunological methods.

[11]  J. Dillner,et al.  Clustering of Seropositivities for Sexually Transmitted Infections , 2002, Sexually transmitted diseases.

[12]  P. Coursaget,et al.  Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus‐like particles in colombian women with invasive cervical cancer , 2002, International journal of cancer.

[13]  S. Nieh,et al.  Viral load of high‐risk human papillomavirus in cervical squamous intraepithelial lesions , 2002, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[14]  P. Saikku,et al.  Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. , 2001, JAMA.

[15]  J. Zenilman.  Chlamydia and cervical cancer: a real association? , 2001, JAMA.

[16]  M. Plummer,et al.  Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. , 2000, Journal of the National Cancer Institute.

[17]  J. Dillner,et al.  Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. , 1999, The Journal of general virology.

[18]  J. Paavonen,et al.  Chlamydia trachomatis: impact on human reproduction. , 1999, Human reproduction update.

[19]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[20]  Mark Woodward,et al.  Epidemiology: Study Design and Data Analysis , 1999 .

[21]  T. Bjørge,et al.  No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11 , 1999, International journal of cancer.

[22]  F. Wiklund,et al.  Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. , 1999, The Journal of general virology.

[23]  L Beardsley,et al.  Natural history of cervicovaginal papillomavirus infection in young women. , 1998, The New England journal of medicine.

[24]  M. Lehtinen,et al.  Stability over time of serum antibody levels to human papillomavirus type 16. , 1998, The Journal of infectious diseases.

[25]  T. Bjørge,et al.  Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. , 1997, Journal of the National Cancer Institute.

[26]  J. Dillner,et al.  Human papillomavirus antibody responses among patients with incident cervical carcinoma , 1997, Journal of medical virology.

[27]  K. Shah,et al.  Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[28]  J. Dillner,et al.  Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. , 1997, Genitourinary medicine.

[29]  R. Lin,et al.  Epidemiology of cervical cancer in Taiwan. , 1996, Gynecologic oncology.

[30]  R. Lin,et al.  Risk factors for cervical intraepithelial neoplasia in Taiwan. , 1996, Gynecologic oncology.

[31]  M. Lehtinen,et al.  Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. , 1996, The Journal of infectious diseases.

[32]  J. Dillner,et al.  Comparison of Development of Serum Antibodies to HPV16 and HPV33 and Acquisition of Cervical HPV DNA Among Sexually Experienced and Virginal Young Girls: A Longitudinal Cohort Study , 1996, Sexually transmitted diseases.

[33]  R. Peto,et al.  Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study , 1996, BMJ.

[34]  C. Meinert,et al.  Human papillomavirus and cervical neoplasia: A case‐control study in Taiwan , 1995, International journal of cancer.

[35]  V. Moreno,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[36]  M. Evander,et al.  Human Papillomavirus Infection Is Transient in Young Women: A PopulationBased Cohort Study , 1995 .

[37]  David R. Scott,et al.  Persistence of type-specific human papillomavirus infection among cytologically normal women. , 1994, The Journal of infectious diseases.

[38]  D. Lowy,et al.  Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles , 1993, Journal of virology.

[39]  J. Ferlay,et al.  Estimates of the worldwide incidence of eighteen major cancers in 1985 , 1993, International journal of cancer.

[40]  S Lemeshow,et al.  Confidence interval estimation of interaction. , 1992, Epidemiology.

[41]  M. Schiffman,et al.  Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. , 1992, Journal of the National Cancer Institute.

[42]  G. Eklund,et al.  Condylomata acuminata and risk of cancer: an epidemiological study. , 1991, BMJ.

[43]  P. Saikku,et al.  Persistence of chlamydial antibodies after pelvic inflammatory disease , 1986, Journal of clinical microbiology.

[44]  S Greenland,et al.  Concepts of interaction. , 1980, American journal of epidemiology.

[45]  S. Wang,et al.  Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test. , 1970, American journal of ophthalmology.

[46]  T. Bjørge,et al.  Chlamydia trachomatis infection as a risk factor for invasive cervical cancer , 2000, International journal of cancer.

[47]  M. Evander,et al.  Human papillomavirus infection is transient in young women: a population-based cohort study. , 1995, The Journal of infectious diseases.